ACR: Actonel (Risedronate) Once-a-Week Proves Equally Effective as Actonel Daily In Postmenopausal Osteoporosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ACR: Actonel (Risedronate) Once-a-Week Proves Equally Effective as Actonel Daily In Postmenopausal Osteoporosis

SAN FRANCISCO, CA -- November 13, 2001 -- A once-a-week dosage of Actonel® (risedronate sodium tablets) 35 mg was as effective as daily Actonel 5 mg at increasing bone mineral density (BMD) in women with postmenopausal osteoporosis (PMO), in a recent study.
Data from the study, which included 1,456 women age 50 and older, were presented today at the 65th Annual Scientific Meeting of the American College of Rheumatology (ACR) in San Francisco, California.

In the study, patients taking Actonel 35 mg once a week experienced a significant 3.9 percent increase in lumbar spine BMD at 12 months versus baseline, comparable to the 4 percent increase achieved with the 5 mg daily dose. Total hip, femoral neck and trochanteric BMD also increased significantly at 12 months versus baseline with both dosages, with differences in BMD increases of less than 0.5 percent between the daily and once-a-week treatments. In addition, the adverse event profile of risedronate 35 mg once a week was comparable to the 5 mg daily dose.

The study included postmenopausal women at least 50 years old with osteoporosis (defined as low lumbar spine BMD, or t-score less than or equal to -2.0 with at least one prior vertebral fracture). All women received calcium supplementation, and some received vitamin D if baseline levels were low.

"These data suggest that once a week use of 35 mg risedronate may be an alternative to daily dosing," said Robert Lindsay, M.D., Ph.D., Helen Hayes Hospital, principal investigator of the study. "I expect that once a week dosing will be an important option for some patients and physicians."

SOURCE: Aventis Pharmaceuticals

Related Link: Aventis Pharmaceuticals.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities